Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MMP2 | P08253 | 3/20 | 0.40 |
| ▸ | MMP9 | P14780 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | AOC2 | O75106 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115280 | 1.00 | CRBN (0.45) | CRBNCA2ALDH1A1NPSR1CYP3A4 | |
| SCHEMBL27802097 | 0.98 | CRBN (0.44) | CRBNCA2ALDH1A1NPSR1CYP3A4 | |
| SCHEMBL22541108 | 0.87 | ALDH1A1 (0.46) | CRBNCA2ALDH1A1NPSR1CYP3A4 | |
| SCHEMBL10759616 | 0.82 | MMP9 (0.41) | CA2ALDH1A1NPSR1CYP3A4MEN1 | |
| SCHEMBL10759604 | 0.82 | CA2 (0.42) | CA2ALDH1A1CYP3A4MEN1KMT2A | |
| SCHEMBL10756282 | 0.82 | MMP9 (0.41) | CA2ALDH1A1NPSR1CYP3A4MEN1 | |
| SCHEMBL10754508 | 0.82 | CA2 (0.42) | CA2ALDH1A1CYP3A4MEN1KMT2A | |
| SCHEMBL10759609 | 0.82 | MMP9 (0.41) | CA2ALDH1A1NPSR1CYP3A4MEN1 | |
| SCHEMBL10754514 | 0.82 | MMP9 (0.41) | CA2ALDH1A1NPSR1CYP3A4MEN1 | |
| SCHEMBL10756278 | 0.82 | MMP9 (0.41) | CA2ALDH1A1NPSR1CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| EP-2523957-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2012-11-21 | — | — | EP | disclosed |
| CN-102712640-A | Tricyclic heterocyclic compounds, compositions and methods of use thereof | HOFFMANN LA ROCHE | 2012-10-03 | — | — | CN | disclosed |
| US-8158663-B2 | N-[2-thiazolylidene- or 2-oxazolylidene]carbo- or heterocyclecarboxyamides, e.g., 5-chloro-2-methoxy-N-[(2Z)-3-(2-methoxyethyl)-5,5-dimethyl-1,3-thiazolidin-2-ylidene]benzamide; treating neuropathic, nociceptive, and inflammatory pain and immune, respiratory, and cardiovascular disorders | ABBOTT LABORATORIES (US) | 2012-04-17 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2011086053-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | disclosed |
| WO-2008079687-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153883-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
| US-20030144319-A1 | Subtype-selective NMDA receptor ligands and the use thereof | BIGGE CHRISTOPHER F (US) | 2003-07-31 | — | — | US | disclosed |
| US-6534522-B2 | E.g.,N-((4-amino-3-nitrophenoxy)ethyl)-1,2,3,4-tetrahydro -isoquinoline; stroke; antiischemic agents; CNS trauma, hyperglycemic agents; surgery; neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis | WARNER-LAMBERT COMPANY | 2003-03-18 | — | — | US | disclosed |
| US-20010051633-A1 | Subtype-selective NMDA receptor ligands and the use thereof | BIGGE CHRISTOPHER F (US) | 2001-12-13 | — | — | US | disclosed |
| US-6218404-B1 | THERAPY AND PROPHYLAXIS OF NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CNS TRAUMA, HYPOGLYCEMIA AND SURGERY, NEURO-DEGENERATIVE DISEASES INCLUDING ALZHEIMER'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, HUNTINGTON'S DISEASE | WARNER-LAMBERT CO. | 2001-04-17 | — | — | US | disclosed |
| WO-1997023458-A1 | SUBTYPE-SELECTIVE NMDA RECEPTOR LIGANDS AND THE USE THEREOF | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144319-A1 | Subtype-selective NMDA receptor ligands and the use thereof | OPRK1, OPRD1, OPRL1 | CRBN 2574/4885CA2 2093/4885ALDH1A1 2672/4885 |
| US-20010051633-A1 | Subtype-selective NMDA receptor ligands and the use thereof | OPRK1, OPRD1, OPRL1 | CRBN 2574/4885CA2 2093/4885ALDH1A1 2672/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | CRBN 1160/4885CA2 3337/4885ALDH1A1 1168/4885 |
| US-20080153883-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, GPR18 | CRBN 1240/4885CA2 3838/4885ALDH1A1 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.